| Name | Title | Contact Details |
|---|
Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara`s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.
Active Pharma is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cherokee Nation Health Services is the largest tribally-operated health system in the country and offers a variety of services to Cherokee Nation citizens, as well as citizens of other federally recognized tribes. Through the health system, the tribe operates eight health centers and W.W. Hastings Hospital within the tribe`s 14-county jurisdiction. On the Hastings campus a 469,000 square foot outpatient health facility will also open this fall.
Rx America is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Rx America is based in Salt Lake City, UT. You can find more information on Rx America at www.rxamerica.com
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.